Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Total Current Liabilities
All obligations due within one year.
Eli Lilly and CompanyNYSE: LLY
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 22.4% from a year ago
Total current liabilities stood at $47.74B at the end of Q2 FY2026, up 22.4% from a year earlier and up 30.3% from the prior quarter. Over 3 fiscal years it compounded at +27.1% a year.
Context
- Total current liabilities amounted to 33.6% of total assets at the end of Q2 FY2026, down 5.1 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +22.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 35.23B USD
- Year-over-year change
- +24.1%
- 4-year CAGR
- +23.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.23B | +24.1% |
| FY2024 | 2024-12-31 | 28.38B | +4.0% |
| FY2023 | 2023-12-31 | 27.29B | +59.3% |
| FY2022 | 2022-12-31 | 17.14B | +13.9% |
| FY2021 | 2021-12-31 | 15.05B | — |
Total Current Liabilities vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +22.4% is the 2nd highest of 10, against a peer median of +6.5%.
- Total current liabilities amounts to 33.6% of total assets for LLY, versus a peer median of 26.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 239.08B DKK | +15.2% | +21.3% | 40.2% | |
| Sep 2026 | $55.46B USD | +9.0% | -1.0% | 28.1% | |
| Jun 2026 | $47.74B USD | +22.4% | +27.1% | 33.6% | |
| Jun 2026 | $41.64B USD | +4.7% | +13.6% | 30.8% | |
| Jun 2026 | $32.65B USD | -13.5% | -4.3% | 16.2% | |
| Jun 2026 | €31.93B EUR | +9.9% | +5.8% | 24.7% | |
| Jun 2026 | $31.75B USD | +0.1% | -1.6% | 26.0% | |
| Sep 2026 | $31.21B USD | -8.3% | +5.2% | 26.1% | |
| Jun 2026 | $27.73B USD | +6.5% | +5.3% | 21.4% | |
| Jun 2026 | $25.5B USD | +24.5% | +17.6% | 26.7% | |
| Peer median (excluding LLY) | — | +6.5% | +5.3% | 26.1% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.82B | 2.07B | 2.82B | 3.27B | 7.16B |
| Short-term Investments | 90.1M | 144.8M | 109.1M | 154.8M | 105M |
| Net Receivables | 8.13B | 8.56B | 11.34B | 13.28B | 20.16B |
| Inventory | 3.89B | 4.31B | 5.77B | 7.59B | 13.74B |
| Other Current Assets | 0 | 7.3M | 149.5M | 111.4M | 147M |
| Total Current Assets | 18.45B | 18.03B | 25.73B | 32.74B | 55.63B |
| Property, Plant & Equipment (Net) | 8.99B | 10.14B | 12.91B | 17.1B | 24.68B |
| Goodwill | 3.89B | 4.07B | 4.94B | 5.77B | 5.9B |
| Intangible Assets | 7.69B | 7.21B | 6.91B | 6.17B | 6.52B |
| Long-term Investments | 3.21B | 2.9B | 3.05B | 3.22B | 2.8B |
| Tax Assets | 2.49B | 2.79B | 5.48B | 8B | 9.96B |
| Other Non-current Assets | 4.08B | 4.34B | 4.99B | 5.72B | 6.99B |
| Total Non-current Assets | 30.35B | 31.46B | 38.28B | 45.98B | 56.85B |
| Total Assets | 48.81B | 49.49B | 64.01B | 78.71B | 112.48B |
| Account Payables | 1.67B | 1.93B | 2.6B | 3.23B | 5.38B |
| Short-term Debt | 1.54B | 1.5B | 6.9B | 5.12B | 1.64B |
| Tax Payables | 126.9M | 475.1M | 3.85B | 0 | 5.88B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.68B | 3.91B | 4.93B | 7.15B | 28.21B |
| Total Current Liabilities | 15.05B | 17.14B | 27.29B | 28.38B | 35.23B |
| Long-term Debt | 15.35B | 14.74B | 18.32B | 28.53B | 40.87B |
| Deferred Tax Liabilities | 1.73B | 87.3M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.52B | 6.75B | 7.53B | 7.54B | 9.85B |
| Total Non-current Liabilities | 24.6B | 21.58B | 25.85B | 36.07B | 50.71B |
| Total Liabilities | 39.65B | 38.71B | 53.14B | 64.44B | 85.94B |
| Common Stock | 596.3M | 594.1M | 593.6M | 592.4M | 590M |
| Retained Earnings | 8.96B | 10.04B | 10.31B | 13.55B | 24.47B |
| Accumulated OCI | (4.34B) | (3.84B) | (4.33B) | (4.32B) | (2.88B) |
| Other Stockholders Equity | (3.01B) | (3.01B) | (3.01B) | (3.01B) | (2.99B) |
| Minority Interest | 175.6M | 125.6M | 91.8M | 79.5M | 0 |
| Total Equity | 9.15B | 10.78B | 10.86B | 14.27B | 26.54B |
| Total Debt | 16.88B | 16.24B | 25.23B | 33.64B | 42.5B |
| Net Debt | 13.07B | 14.17B | 22.41B | 30.38B | 35.34B |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.